Cochrane Abstracts
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Eslicarbazepine Acetate Add‐on Therapy for Drug‐resistant Focal Epilepsy." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439259/all/Eslicarbazepine_acetate_add‐on_therapy_for_drug‐resistant_focal_epilepsy.
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439259/all/Eslicarbazepine_acetate_add‐on_therapy_for_drug‐resistant_focal_epilepsy. Accessed November 22, 2024.
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439259/all/Eslicarbazepine_acetate_add‐on_therapy_for_drug‐resistant_focal_epilepsy
Eslicarbazepine Acetate Add‐on Therapy for Drug‐resistant Focal Epilepsy [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 November 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439259/all/Eslicarbazepine_acetate_add‐on_therapy_for_drug‐resistant_focal_epilepsy.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy
ID - 439259
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439259/all/Eslicarbazepine_acetate_add‐on_therapy_for_drug‐resistant_focal_epilepsy
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
